Press Release: Vedanta : Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies with an initial focus on gastrointestinal diseases, today announced the oral presentation of additional analyses from its completed Phase 2 CONSORTIUM study of VE303, an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent Clostridioides difficile infection (rCDI). These analyses document the